It is time to move beyond DRGs and embrace a new framework to create more sustainable healthcare models.

In this technical review, we will take a look at the unintended consequences of the IRA’s Medicare negotiations on ASP-based Part B in-office administered products.

In this part two, we discuss what is required for success in market access efforts as well as how to avoid common pitfalls.

In this article, we explore an initial impact analysis of Trump's 'Most Favored Nations' executive order which will put enormous pressure on the industry.

Learn more about the crossroads we are at to lower U.S. healthcare costs and saving Medicare and Medicaid for future generations.

To execute IEPs that allow companies to realize the full value of their products, several historical flaws must be addressed. In part one, we explore four of those critical themes.

The latest wave of pharma layoffs – at Moderna, at Biogen, at Johnson & Johnson and beyond – reflects the financial pressures reshaping the industry.

This primer examines how pharmaceutical investment decisions must consider market access factors to be effective.

PhRMA has made numerous statements about the IRA negatively impacting innovation. Learn what the seven primary areas of R&D are that are being targeted for reduction.

Part two discussion where we’ll dive into an example of where Pharma Executives have failed to have, or utilize, a strategic vision for the future.